341 related articles for article (PubMed ID: 20368564)
1. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.
Tsien C; Galbán CJ; Chenevert TL; Johnson TD; Hamstra DA; Sundgren PC; Junck L; Meyer CR; Rehemtulla A; Lawrence T; Ross BD
J Clin Oncol; 2010 May; 28(13):2293-9. PubMed ID: 20368564
[TBL] [Abstract][Full Text] [Related]
2. The parametric response map is an imaging biomarker for early cancer treatment outcome.
Galbán CJ; Chenevert TL; Meyer CR; Tsien C; Lawrence TS; Hamstra DA; Junck L; Sundgren PC; Johnson TD; Ross DJ; Rehemtulla A; Ross BD
Nat Med; 2009 May; 15(5):572-6. PubMed ID: 19377487
[TBL] [Abstract][Full Text] [Related]
3. Perfusion magnetic resonance imaging for parametric response maps in tumors: is it really that easy?
Heiland S; Wick W; Bendszus M
J Clin Oncol; 2010 Oct; 28(29):e591; author reply e592. PubMed ID: 20837945
[No Abstract] [Full Text] [Related]
4. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
[TBL] [Abstract][Full Text] [Related]
5. Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.
Law M; Young R; Babb J; Rad M; Sasaki T; Zagzag D; Johnson G
AJNR Am J Neuroradiol; 2006 Oct; 27(9):1975-82. PubMed ID: 17032878
[TBL] [Abstract][Full Text] [Related]
6. Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment.
Galbán CJ; Chenevert TL; Meyer CR; Tsien C; Lawrence TS; Hamstra DA; Junck L; Sundgren PC; Johnson TD; Galbán S; Sebolt-Leopold JS; Rehemtulla A; Ross BD
Clin Cancer Res; 2011 Jul; 17(14):4751-60. PubMed ID: 21527563
[TBL] [Abstract][Full Text] [Related]
7. Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
Lee WJ; Choi SH; Park CK; Yi KS; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH
Acad Radiol; 2012 Nov; 19(11):1353-61. PubMed ID: 22884399
[TBL] [Abstract][Full Text] [Related]
8. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas.
Baek HJ; Kim HS; Kim N; Choi YJ; Kim YJ
Radiology; 2012 Sep; 264(3):834-43. PubMed ID: 22771885
[TBL] [Abstract][Full Text] [Related]
9. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.
Gahramanov S; Muldoon LL; Varallyay CG; Li X; Kraemer DF; Fu R; Hamilton BE; Rooney WD; Neuwelt EA
Radiology; 2013 Mar; 266(3):842-52. PubMed ID: 23204544
[TBL] [Abstract][Full Text] [Related]
10. Assesment of perfusion in glial tumors with arterial spin labeling; comparison with dynamic susceptibility contrast method.
Cebeci H; Aydin O; Ozturk-Isik E; Gumus C; Inecikli F; Bekar A; Kocaeli H; Hakyemez B
Eur J Radiol; 2014 Oct; 83(10):1914-9. PubMed ID: 25087109
[TBL] [Abstract][Full Text] [Related]
11. High-grade and low-grade gliomas: differentiation by using perfusion MR imaging.
Hakyemez B; Erdogan C; Ercan I; Ergin N; Uysal S; Atahan S
Clin Radiol; 2005 Apr; 60(4):493-502. PubMed ID: 15767107
[TBL] [Abstract][Full Text] [Related]
12. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
13. Echo-planar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weighting.
Bruening R; Kwong KK; Vevea MJ; Hochberg FH; Cher L; Harsh GR; Niemi PT; Weisskoff RM; Rosen BR
AJNR Am J Neuroradiol; 1996 May; 17(5):831-40. PubMed ID: 8733954
[TBL] [Abstract][Full Text] [Related]
14. Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation?
Danchaivijitr N; Waldman AD; Tozer DJ; Benton CE; Brasil Caseiras G; Tofts PS; Rees JH; Jäger HR
Radiology; 2008 Apr; 247(1):170-8. PubMed ID: 18372467
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
Nasseri M; Gahramanov S; Netto JP; Fu R; Muldoon LL; Varallyay C; Hamilton BE; Neuwelt EA
Neuro Oncol; 2014 Aug; 16(8):1146-54. PubMed ID: 24523362
[TBL] [Abstract][Full Text] [Related]
16. Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.
Thomsen H; Steffensen E; Larsson EM
Acta Radiol; 2012 Feb; 53(1):95-101. PubMed ID: 22114021
[TBL] [Abstract][Full Text] [Related]
17. Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.
Netto JP; Schwartz D; Varallyay C; Fu R; Hamilton B; Neuwelt EA
Fluids Barriers CNS; 2016 Dec; 13(1):23. PubMed ID: 27998280
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
[TBL] [Abstract][Full Text] [Related]
19. Parametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma.
Ceschin R; Kurland BF; Abberbock SR; Ellingson BM; Okada H; Jakacki RI; Pollack IF; Panigrahy A
AJNR Am J Neuroradiol; 2015 Nov; 36(11):2170-6. PubMed ID: 26338910
[TBL] [Abstract][Full Text] [Related]
20. True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis.
Song YS; Choi SH; Park CK; Yi KS; Lee WJ; Yun TJ; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Jahng GH; Chang KH
Korean J Radiol; 2013; 14(4):662-72. PubMed ID: 23901325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
